Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.

Rhea-AI Summary

SOPHiA GENETICS (NASDAQ:SOPH) partnered with Synnovis to deliver MSK-ACCESS® liquid biopsy testing, powered by SOPHiA DDM™, to lung and breast cancer patients across the U.K. within NHS England’s blood test-first program.

The ctDNA-based test supports about 400 patients per month and is expected to reach 7,000 patients annually, potentially covering roughly one third of all ctDNA tests in England and enabling targeted therapies up to two weeks earlier.

AI-generated analysis. Not financial advice.

Positive

• ctDNA liquid biopsy currently supports about 400 patients per month
• Application expected to test approximately 7,000 breast and lung cancer patients annually
• Programme anticipated to cover roughly one third of ctDNA tests in England
• Liquid biopsy may enable targeted therapy up to two weeks earlier
• Platform allows Synnovis to add future NHS cancer screening indications
• Matched tumor-normal approach and AccuGenomics® technology aim to reduce false positives

Negative

• None.

News Market Reaction – SOPH

-2.59%

4 alerts

-2.59% News Effect

-6.4% Trough Tracked

-$9M Valuation Impact

$351.08M Market Cap

0.3x Rel. Volume

On the day this news was published, SOPH declined 2.59%, reflecting a moderate negative market reaction. Argus tracked a trough of -6.4% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $9M from the company's valuation, bringing the market cap to $351.08M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patients per month: 400 patients Annual testing volume: 7,000 patients Testing share in England: One third +5 more

8 metrics

Patients per month 400 patients ctDNA liquid biopsy testing currently supported by Synnovis

Annual testing volume 7,000 patients Expected yearly breast and lung cancer patients tested via program

Testing share in England One third Rough portion of all ctDNA tests in England via this program

Treatment acceleration Two weeks earlier Potential speed-up for targeted therapy using blood-based testing

Breast cancer duration More than 15 years Duration of disease in a highlighted breast cancer case

Oncology patients treated 4,000 patients Annual oncology patients at Mount Sinai in prior collaboration

Hands-on time reduction 30–50% reduction Operational improvements targeted in Jessa Ziekenhuis partnership

Cost reduction target Up to 25% Cost reduction goal from prior hospital partnership deployment

Market Reality Check

Price: $5.00 Vol: Volume 201,733 is 1.79x t...

high vol

$5.00 Last Close

Volume Volume 201,733 is 1.79x the 20-day average of 112,536, indicating elevated interest ahead of this news. high

Technical Shares at $4.63 are trading above the 200-day MA at $4.45, but sit 18.77% below the 52-week high of $5.70.

Peers on Argus

SOPH was down 3.34% while momentum peers showed mixed moves (e.g., MNDR up 3.38%...

1 Up 1 Down

SOPH was down 3.34% while momentum peers showed mixed moves (e.g., MNDR up 3.38%, OPRX down 6.31%) and no same-day peer news, pointing to a stock-specific setup around this partnership.

Previous Partnership Reports

3 past events · Latest: Sep 22 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Sep 22	Oncology partnership	Positive	+18.4%	Expanded AstraZeneca collaboration to enhance breast and prostate cancer detection.
Sep 05	Hospital partnership	Positive	-5.0%	Strategic deal with Belgian hospital Jessa to deploy SOPHiA DDM platform.
Apr 08	Biopharma partnership	Positive	-1.1%	Precision for Medicine partnership integrating SOPHiA DDM and liquid biopsy in trials.

Pattern Detected

Partnership headlines have generally been positive but produced mixed reactions, with one strong gain and two selloffs, suggesting market responses to such deals are inconsistent.

Recent Company History

Over the past year, SOPH has announced several oncology-focused partnerships. A Sep 22, 2025 collaboration with AstraZeneca on AI-enhanced breast and prostate cancer detection saw the stock rise 18.37%. However, a Sep 5, 2025 hospital partnership and an Apr 8, 2025 biopharma services deal both saw modest negative moves. Today’s NHS-linked Synnovis agreement fits this pattern of expanding AI-driven liquid biopsy and genomic testing collaborations.

Historical Comparison

+4.1% avg move · In the past year, SOPH announced 3 partnership deals, with an average 4.09% move and mixed single-da...

partnership

+4.1%

Average Historical Move partnership

In the past year, SOPH announced 3 partnership deals, with an average 4.09% move and mixed single-day reactions. The new NHS-focused Synnovis collaboration continues this theme of oncology-driven platform adoption.

Partnerships have evolved from biopharma trial support and European hospital integrations to a large-scale AstraZeneca cancer program and now broad NHS-linked liquid biopsy access via Synnovis.

Regulatory & Risk Context

Active S-3 Shelf · $388,717.50

Shelf Active

Active S-3 Shelf Registration 2026-03-03

$388,717.50 registered capacity

An effective F-3 filed on 2026-03-03 registers up to 75,000 warrant shares for resale. If fully exercised at $5.1829, SOPH may receive up to $388,717.50 for working capital and general corporate purposes.

Market Pulse Summary

This announcement highlights a significant expansion of SOPH’s liquid biopsy footprint via Synnovis,...

Analysis

This announcement highlights a significant expansion of SOPH’s liquid biopsy footprint via Synnovis, supporting about 400 patients monthly and targeting 7,000 lung and breast cancer patients annually—roughly one third of England’s ctDNA tests. It builds on prior oncology collaborations and showcases real-world NHS integration. Investors may watch uptake trends, incremental application additions, and how this usage translates into platform volumes alongside existing regulatory and capital-structure disclosures.

Key Terms

liquid biopsy, circulating tumor DNA (ctDNA), genomic alterations, genomic testing, +3 more

7 terms

liquid biopsy medical

"to bring liquid biopsy testing to lung and breast cancer patients across the U.K."

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

circulating tumor DNA (ctDNA) medical

"to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner."

Circulating tumor DNA (ctDNA) are tiny fragments of genetic material shed by cancer cells into the bloodstream, detectable with a blood test often called a liquid biopsy. For investors, ctDNA matters because it can enable earlier, less invasive detection of cancer, track how well treatments are working, and guide drug development and diagnostic products—factors that can drive demand, regulatory decisions, and company valuations in oncology-related markets.

genomic alterations medical

"detects actionable genomic alterations from a single blood draw"

Genomic alterations are changes to an organism’s DNA—like typos, missing lines, or extra copies in the genetic instruction manual—that can change how cells behave. Investors care because these changes can drive disease, create targets for new drugs or tests, and influence a company’s ability to develop, approve, and sell therapies or diagnostics; in other words, they can significantly affect clinical success and future revenue.

genomic testing medical

"substantially expand the reach and impact of genomic testing services"

A laboratory process that reads and analyzes a person’s DNA to identify genetic variations linked to disease risk, treatment response, or drug targets; think of it as reading a biological blueprint to predict problems and guide medical choices. Investors care because results drive demand for certain diagnostics, targeted therapies, and clinical trial designs, so advances, approvals, or reimbursement changes can directly affect revenue prospects and the value of healthcare companies.

tumor-normal approach medical

"utilizes a matched tumor-normal approach as well as technology from AccuGenomics"

A tumor-normal approach compares genetic material from a patient’s tumor with DNA from their healthy tissue to tell which mutations are specific to the cancer and which are inherited. It’s like comparing an edited document to the original to spot changes: this clarity improves accuracy of diagnoses, helps identify targeted treatments, and reduces false signals that can mislead drug development or diagnostic tests—information investors use to assess clinical and commercial risk.

precision medicine medical

"a global leader in Ai-driven precision medicine, today announced a partnership"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

pathology medical

"one of England's leading pathology providers, to bring liquid biopsy testing"

Pathology is the medical study and lab testing of disease, usually involving examination of tissue, blood, or other samples to determine what is wrong and why. For investors, pathology findings act like a forensic report for a drug, device, or diagnostic: they can confirm whether a treatment works, reveal safety issues, influence regulatory approval and market demand, and therefore affect a health‑care company’s prospects and valuation.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's 'revolutionary blood test-first' program.

Synnovis, a major provider for England's South East Genomic Medicine Service, worked with SOPHiA GENETICS to launch the liquid biopsy test MSK-ACCESS^® powered with SOPHiA DDM™. This innovative test, originally developed by Memorial Sloan Kettering Cancer Center in New York, detects actionable genomic alterations from a single blood draw and leverages state-of-the-art Ai to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner.

The new blood-based test offered by Synnovis can help fast-track cancer patients to receive targeted therapy up to two weeks earlier, while helping some avoid further tests and invasive treatments such as chemotherapy.

Following the successful pilot program, Synnovis is already supporting approximately 400 patients per month with ctDNA liquid biopsy testing and is demonstrating the real-world impact of this advanced care. In one case, a patient with suspected advanced lung cancer was able to receive a ctDNA-informed personalised treatment plan within just two weeks. In another case, providers used SOPHiA DDM™ to identify new genetic variants for a patient who had been living with breast cancer for more than 15 years, unlocking additional treatment options and potential eligibility for clinical trials.

Synnovis and SOPHiA GENETICS anticipate that the application will be used to test approximately 7,000 breast and lung cancer patients annually, or roughly one third of all ctDNA tests in England, as the demand for liquid biopsy testing increases.

Persephone du Parcq, MSc., Lead Translational Scientist, Synnovis, said: "Liquid biopsy testing simplifies how we generate genomic insights. A routine blood draw can reveal information from multiple tumour sites and speed up delivery of results to the patients. It also broadens access for patients who cannot tolerate invasive procedures or travel to specialist hospitals. As adoption increases, this approach will substantially expand the reach and impact of genomic testing services, and we anticipate economic savings for healthcare providers and better outcomes for greater numbers of patients."

Ross Muken, President, SOPHiA GENETICS, said: "Synnovis plays a vital role in delivering genomic testing services to patients across South East England, and this partnership reflects what becomes possible when world-class pathology infrastructure meets scalable Ai-driven analysis. With roughly one third of all ctDNA testing in England expected to run through this programme, we see this as a defining moment for liquid biopsy at scale within the NHS, and a model for how health systems in Europe can make precision oncology accessible."

Beyond accelerating targeted treatments, MSK-ACCESS^® powered with SOPHiA DDM™ provides Synnovis with the flexibility to incorporate additional indications as they are introduced into future NHS cancer screening programs. It also utilizes a matched tumor-normal approach as well as technology from AccuGenomics^® to improve accuracy and avoid false positives.

Leading laboratories like Synnovis are helping bring NHS England's 'blood test-first' approach to scale through innovative solutions, contributing to a sustainable, data-driven approach to cancer care across the United Kingdom. By strengthening its genomic testing infrastructure, Synnovis joins a growing network of NHS institutions using SOPHiA GENETICS' technology to conduct local analysis, maintain alignment with NHS data-security standards, and support the operational model of distributed analysis hubs.

To learn more about how Synnovis deployed ctDNA testing for the patients it serves, view a webinar presented by one of the laboratory's lead scientists. 

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is an Ai-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an Ai platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

About Synnovis
Synnovis is a partnership between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust, performing more than 32 million pathology tests a year across a network of routine and specialist laboratories. Serving a population of 1.7 million in south east London, we bring together the very best in clinical, scientific and operational expertise to provide a pathology service which aims to create better outcomes for patients and make a positive difference to people's health and wellbeing. We work collaboratively with the NHS, SYNLAB, clinical users and other stakeholders – every sample we process represents an individual patient in our joint care, and we understand the important role we play in continually developing services to meet that important responsibility.

SOPHiA GENETICS Forward-Looking Statements: 
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/synnovis-and-sophia-genetics-partner-to-bring-blood-based-cancer-testing-to-patients-across-the-uk-302770165.html

SOURCE SOPHiA GENETICS

FAQ

What did SOPHiA GENETICS (NASDAQ:SOPH) announce with Synnovis on May 13, 2026?

SOPHiA GENETICS announced a partnership with Synnovis to provide MSK-ACCESS® liquid biopsy testing for lung and breast cancer patients across the U.K. According to SOPHiA GENETICS, this supports NHS England’s blood test-first program using Ai-driven ctDNA analysis.

How many patients will the SOPH and Synnovis liquid biopsy program serve each year?

The program is anticipated to test approximately 7,000 breast and lung cancer patients annually. According to SOPHiA GENETICS, this volume represents roughly one third of all ctDNA tests performed in England as demand for liquid biopsy grows.

How can the SOPHiA GENETICS and Synnovis ctDNA test affect treatment timelines?

The blood-based ctDNA test can help fast-track targeted therapy by up to two weeks. According to Synnovis, quicker genomic insights from a routine blood draw may reduce the need for additional tests and some invasive procedures like chemotherapy.

What technology underpins the SOPH MSK-ACCESS® liquid biopsy used by Synnovis?

The test uses MSK-ACCESS® powered with SOPHiA DDM™ to analyze circulating tumor DNA. According to SOPHiA GENETICS, it combines a matched tumor-normal approach with AccuGenomics® technology to improve accuracy and help avoid false-positive genomic findings.

How many patients per month are currently supported by the SOPH ctDNA testing at Synnovis?

Synnovis is already supporting approximately 400 patients per month with ctDNA liquid biopsy testing. According to Synnovis, real-world cases show rapid personalized treatment planning and identification of new genetic variants that can open additional therapeutic and clinical trial options.

What role does SOPHiA GENETICS technology play in NHS England’s blood test-first cancer strategy?

SOPHiA GENETICS technology supports NHS England’s blood test-first approach by enabling scalable, local ctDNA analysis. According to SOPHiA GENETICS, Synnovis and other NHS laboratories use its platform to strengthen genomic infrastructure and align with NHS data-security and distributed analysis requirements.